Novo Nordisk and OpenAI Join Forces to Expedite Drug Discovery
On Tuesday, Danish pharmaceutical titan Novo Nordisk declared a strategic alliance with OpenAI. The aim is to incorporate artificial intelligence throughout their entire business operations. This includes everything from drug discovery to manufacturing and commercial activities.
Through this collaboration, Novo Nordisk, the producer of renowned weight-loss drugs Ozempic and Wegovy, will be able to analyze intricate datasets on an unprecedented scale. This will facilitate the identification of promising drug candidates more rapidly and decrease the time needed to transition new treatments from research to patients. Moreover, the partnership will provide an opportunity to augment AI literacy across departments by upskilling the company’s global workforce.
“There are millions of people living with obesity and diabetes who need treatment options. We know there are therapies still waiting to be discovered that could change their lives,” stated Novo CEO Mike Doustdar.
Pilot programs are set to be launched across research and development, manufacturing, and commercial operations. The expectation is for full integration to be accomplished by the end of 2026.
Novo’s partnership with OpenAI comes at a time when it is in stiff competition with U.S. rival Eli Lilly for dominance in the lucrative weight-loss drug market. Analysts predict that this market could surpass $100 billion in annual revenue over the next decade. The financial terms of the deal, however, have not been disclosed.
Source: CNBC